CHF 4.1
(-6.82%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 114.94 Million CHF | -63.11% |
2022 | 24.52 Million CHF | -7.9% |
2021 | 26.62 Million CHF | 37.96% |
2020 | 19.29 Million CHF | 1939.96% |
2019 | 946 Thousand CHF | 20.05% |
2018 | 788 Thousand CHF | -36.55% |
2017 | 1.24 Million CHF | -28.5% |
2016 | 1.73 Million CHF | -12.83% |
2015 | 1.99 Million CHF | -90.27% |
2014 | 20.47 Million CHF | 8.96% |
2013 | 18.79 Million CHF | 318.19% |
2012 | 4.49 Million CHF | -92.4% |
2011 | 59.16 Million CHF | 201.34% |
2010 | 19.63 Million CHF | -24.04% |
2009 | 25.84 Million CHF | 9.0% |
2008 | 23.71 Million CHF | 43.19% |
2007 | 16.56 Million CHF | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 3.14 Million CHF | 0.0% |
2023 Q2 | 5.92 Million CHF | 0.0% |
2023 FY | 9.04 Million CHF | -63.11% |
2023 Q4 | 3.11 Million CHF | 0.0% |
2022 FY | 24.52 Million CHF | -7.9% |
2022 Q2 | 15.74 Million CHF | 0.0% |
2022 Q4 | 8.77 Million CHF | 0.0% |
2021 Q2 | 14.95 Million CHF | 0.0% |
2021 Q4 | 14.62 Million CHF | 0.0% |
2021 FY | 26.62 Million CHF | 37.96% |
2020 Q2 | 3.5 Million CHF | 0.0% |
2020 FY | 19.29 Million CHF | 1939.96% |
2020 Q4 | 15.79 Million CHF | 0.0% |
2019 Q2 | 420 Thousand CHF | 0.0% |
2019 FY | 946 Thousand CHF | 20.05% |
2019 Q4 | 526 Thousand CHF | 0.0% |
2018 Q2 | 422 Thousand CHF | 0.0% |
2018 Q4 | 366 Thousand CHF | 0.0% |
2018 FY | 788 Thousand CHF | -36.55% |
2017 FY | 1.24 Million CHF | -28.5% |
2017 Q4 | 692 Thousand CHF | 0.0% |
2017 Q2 | 1.05 Million CHF | 0.0% |
2016 Q1 | 434.25 Thousand CHF | 0.0% |
2016 FY | 1.73 Million CHF | -12.83% |
2016 Q2 | 271 Thousand CHF | -37.59% |
2016 Q4 | 16.34 Million CHF | 0.0% |
2015 Q3 | 478.46 Thousand CHF | 0.0% |
2015 FY | 1.99 Million CHF | -90.27% |
2015 Q1 | 478.46 Thousand CHF | 0.0% |
2015 Q4 | 434.25 Thousand CHF | -9.24% |
2015 Q2 | 478.46 Thousand CHF | 0.0% |
2014 Q4 | 478.46 Thousand CHF | -89.36% |
2014 FY | 20.47 Million CHF | 8.96% |
2014 Q3 | 4.49 Million CHF | 0.0% |
2014 Q2 | 4.49 Million CHF | 0.0% |
2014 Q1 | 4.49 Million CHF | 0.0% |
2013 Q4 | 4.49 Million CHF | 436.82% |
2013 Q3 | 837.61 Thousand CHF | 0.0% |
2013 Q2 | 837.61 Thousand CHF | 0.0% |
2013 Q1 | 837.61 Thousand CHF | 0.0% |
2013 FY | 18.79 Million CHF | 318.19% |
2012 FY | 4.49 Million CHF | -92.4% |
2012 Q4 | 837.61 Thousand CHF | -45.78% |
2012 Q2 | 1.54 Million CHF | 0.0% |
2012 Q1 | 1.54 Million CHF | 0.0% |
2012 Q3 | 1.54 Million CHF | 0.0% |
2011 Q2 | 14.79 Million CHF | 0.0% |
2011 Q4 | 1.54 Million CHF | -89.56% |
2011 FY | 59.16 Million CHF | 201.34% |
2011 Q3 | 14.79 Million CHF | 0.0% |
2011 Q1 | 14.79 Million CHF | 0.0% |
2010 Q1 | 4.9 Million CHF | 0.0% |
2010 Q4 | 14.79 Million CHF | 201.34% |
2010 Q3 | 4.9 Million CHF | 0.0% |
2010 Q2 | 4.9 Million CHF | 0.0% |
2010 FY | 19.63 Million CHF | -24.04% |
2009 Q2 | 6.46 Million CHF | 0.0% |
2009 Q3 | 6.46 Million CHF | 0.0% |
2009 Q4 | 4.9 Million CHF | -24.04% |
2009 FY | 25.84 Million CHF | 9.0% |
2009 Q1 | 6.46 Million CHF | 0.0% |
2008 Q4 | 6.46 Million CHF | 9.0% |
2008 Q2 | 5.92 Million CHF | 0.0% |
2008 Q1 | 5.92 Million CHF | 0.0% |
2008 FY | 23.71 Million CHF | 43.19% |
2008 Q3 | 5.92 Million CHF | 0.0% |
2007 FY | 16.56 Million CHF | 0.0% |
2007 Q3 | 4.14 Million CHF | 0.0% |
2007 Q2 | 4.14 Million CHF | 0.0% |
2007 Q1 | 4.14 Million CHF | 0.0% |
2007 Q4 | 5.92 Million CHF | 43.19% |
2006 Q4 | 4.14 Million CHF | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Addex Therapeutics Ltd | 11.89 Million CHF | -866.358% |
BB Biotech AG | -199.56 Million CHF | 157.595% |
Basilea Pharmaceutica AG | 111.63 Million CHF | -2.961% |
Evolva Holding SA | 89.66 Million CHF | -28.193% |
Idorsia Ltd | 400.38 Million CHF | 71.292% |
Kuros Biosciences AG | 36.21 Million CHF | -217.35% |
Molecular Partners AG | 20.3 Million CHF | -466.156% |
Santhera Pharmaceuticals Holding AG | 31.33 Million CHF | -266.813% |